分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

EphA2 Promotes the Development of Cervical Cancer through the CXCL11/PD-L1 Pathway

Xinyue Zhao, Jiaxi Liu, Dongdong Jin, Chenchen Ren, Li Yang, Yuanhang Zhu, Changhao Huang, Leilei Ding, Zimeng Wu, Ke Shen, Zhen’an Zhang, Huanhuan Chen, Nannan Wang

Journal:Journal of Oncology

IF:4.5

DOI:10.1155/2022/4886907

PMID:36478746

Published:2022-11-28

research field:肿瘤学分子生物学癌症生物学免疫学基因组学

Abstract

Erythropoietin-producing hepatoma receptor A2 (EphA2), receptor tyrosine kinase, the most widespread member of the largest receptor tyrosine kinase family, plays a critical role in physiological and pathological conditions. In recent years, the role of EphA2 in the occurrence and development of cancer has become a research hotspot and is considered a promising potential target. Our previous studies have shown that EphA2 has an indisputable cancer-promoting role in cervical cancer, but its related mechanism requires further research. In this study, high-throughput sequencing was performed on EphA2 knockdown cervical cancer cells and the control group. An analysis of differentially expressed genes revealed that EphA2 may exert its cancer-promoting effect through C-X-C motif chemokine ligand 11 (CXCL11). In addition, we found that EphA2 could further regulate programmed cell death ligand 1 (PD-L1) through CXCL11. This has also been further demonstrated in in vivo experiments. Our study demonstrated that EphA2 plays a tumor-promoting role in cervical carcinoma through the CXCL11/PD-L1 pathway, providing new guidance for the targeted therapy and combination therapy of cervical carcinoma.

本文使用的Yeasen产品

购物车
客服
转染试用